Protalix Biotherapeutics Company Profile (NYSEMKT:PLX)

About Protalix Biotherapeutics (NYSEMKT:PLX)

Protalix Biotherapeutics logoProtalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx. Using its ProCellEx system, the Company is developing a pipeline of biosimilar or generic versions of recombinant therapeutic proteins based on its plant cell-based expression technology, which focuses pharmaceutical markets and that rely upon known biological mechanisms of action. ProCellEx protein expression system consists of a set of technologies and capabilities for the development of recombinant proteins, including advanced genetic engineering technology and plant cell-based protein expression methods. Its ProCellEx protein expression system is built on flexible custom-designed bioreactors made of polyethylene and optimized for the development of complex proteins in plant cell cultures. In June 2010, it had completed the preliminary phase I clinical trial of PRX-105.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NYSEMKT:PLX
  • CUSIP: N/A
  • Web: www.protalix.com
Capitalization:
  • Market Cap: $81.77 million
  • Outstanding Shares: 133,355,000
Average Prices:
  • 50 Day Moving Avg: $0.58
  • 200 Day Moving Avg: $0.86
  • 52 Week Range: $0.26 - $1.51
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.41
  • P/E Growth: -0.11
Sales & Book Value:
  • Annual Revenue: $16 million
  • Price / Sales: 5.11
  • Book Value: ($0.16) per share
  • Price / Book: -3.83
Profitability:
  • EBIDTA: ($30,580,000.00)
Misc:
  • Average Volume: 627,002 shs.
  • Beta: 0.95
 

Frequently Asked Questions for Protalix Biotherapeutics (NYSEMKT:PLX)

What is Protalix Biotherapeutics' stock symbol?

Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "PLX."

How were Protalix Biotherapeutics' earnings last quarter?

Protalix Biotherapeutics Inc (NYSEMKT:PLX) announced its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.02. The company earned $6.36 million during the quarter, compared to analysts' expectations of $5.05 million. View Protalix Biotherapeutics' Earnings History.

Where is Protalix Biotherapeutics' stock going? Where will Protalix Biotherapeutics' stock price be in 2017?

3 brokerages have issued 12 month target prices for Protalix Biotherapeutics' shares. Their predictions range from $1.00 to $5.00. On average, they expect Protalix Biotherapeutics' share price to reach $3.67 in the next twelve months. View Analyst Ratings for Protalix Biotherapeutics.

Who are some of Protalix Biotherapeutics' key competitors?

Who owns Protalix Biotherapeutics stock?

Protalix Biotherapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include California Public Employees Retirement System (0.63%), Virtu KCG Holdings LLC (0.56%) and OxFORD Asset Management LLP (0.54%). Company insiders that own Protalix Biotherapeutics stock include Camber Capital Management Llc, Moshe Manor and Yossi Maimon. View Institutional Ownership Trends for Protalix Biotherapeutics.

Who bought Protalix Biotherapeutics stock? Who is buying Protalix Biotherapeutics stock?

Protalix Biotherapeutics' stock was bought by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC and OxFORD Asset Management LLP. Company insiders that have bought Protalix Biotherapeutics stock in the last two years include Camber Capital Management Llc, Moshe Manor and Yossi Maimon. View Insider Buying and Selling for Protalix Biotherapeutics.

How do I buy Protalix Biotherapeutics stock?

Shares of Protalix Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Protalix Biotherapeutics' stock price today?

One share of Protalix Biotherapeutics stock can currently be purchased for approximately $0.61.


MarketBeat Community Rating for Protalix Biotherapeutics (NYSEMKT PLX)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  131 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  251
MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Protalix Biotherapeutics (NYSEMKT:PLX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.67

Analysts' Ratings History for Protalix Biotherapeutics (NYSEMKT:PLX)
Show:
DateFirmActionRatingPrice TargetDetails
8/10/2017HC WainwrightSet Price TargetBuy$5.00View Rating Details
5/23/2017Rodman & RenshawReiterated RatingBuy$5.00View Rating Details
12/15/2016MackieReiterated RatingBuy$1.00View Rating Details
9/6/2016Jefferies Group LLCLower Price TargetBuy$1.75 -> $0.80View Rating Details
(Data available from 9/20/2015 forward)

Earnings

Earnings History for Protalix Biotherapeutics (NYSEMKT:PLX)
Earnings by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Earnings History by Quarter for Protalix Biotherapeutics (NYSEMKT PLX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/20176/30/2017($0.04)($0.06)$5.05 million$6.36 millionViewListenView Earnings Details
5/10/2017Q1 17($0.09)($0.07)$2.55 million$2.89 millionViewN/AView Earnings Details
8/8/2016Q2 16($0.08)($0.11)$1.34 million$1.77 millionViewN/AView Earnings Details
3/8/2016Q415($0.29)$3.50 million$4.40 millionViewN/AView Earnings Details
11/9/2015Q3 15($0.08)($0.04)$5.00 million$4.30 millionViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.05)$6.40 million$3.78 millionViewN/AView Earnings Details
5/7/2015Q1 15($0.08)($0.06)$8.20 million$4.39 millionViewN/AView Earnings Details
8/7/2014($0.07)($0.07)$9.63 million$2.43 millionViewN/AView Earnings Details
5/8/2014($0.07)($0.08)$8.25 million$6.70 millionViewN/AView Earnings Details
3/13/2014Q413($0.02)($0.12)$5.54 million$2.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Protalix Biotherapeutics (NYSEMKT:PLX)
Current Year EPS Consensus Estimate: $-0.2300 EPS
Next Year EPS Consensus Estimate: $-0.1800 EPS

Dividends

Dividend History for Protalix Biotherapeutics (NYSEMKT:PLX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Protalix Biotherapeutics (NYSEMKT:PLX)
Insider Trades by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Institutional Ownership by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Insider Trades by Quarter for Protalix Biotherapeutics (NYSEMKT:PLX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/16/2017Moshe ManorCEOBuy50,000$0.81$40,500.00View SEC Filing  
12/2/2016Camber Capital Management LlcMajor ShareholderSell2,500,000$0.32$800,000.00View SEC Filing  
12/14/2015Yossi MaimonCFOBuy10,000$0.78$7,800.00View SEC Filing  
10/19/2015Camber Capital Management LlcMajor ShareholderBuy4,000,423$1.00$4,000,423.00View SEC Filing  
8/15/2013Alfred AkirovDirectorSell112,330$5.05$567,266.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Protalix Biotherapeutics (NYSEMKT:PLX)
Latest Headlines for Protalix Biotherapeutics (NYSEMKT:PLX)
Source:
DateHeadline
globenewswire.com logoProtalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 5 at 10:27 PM
finance.yahoo.com logoProtalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 8:20 AM
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - August 15 at 6:40 PM
finance.yahoo.com logoEdited Transcript of PLX earnings conference call or presentation 9-Aug-17 12:30pm GMT
finance.yahoo.com - August 11 at 7:36 AM
americanbankingnews.com logoProtalix Biotherapeutics Inc (NYSEMKT:PLX) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 10 at 2:36 PM
seekingalpha.com logoProtalix BioTherapeutics' (PLX) CEO Moshe Manor on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 10 at 6:54 AM
finance.yahoo.com logoProtalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update
finance.yahoo.com - August 10 at 6:54 AM
finance.yahoo.com logoProtalix posts 2Q profit
finance.yahoo.com - August 10 at 6:54 AM
finance.yahoo.com logoInvestor Network: Protalix BioTherapeutics, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 6:28 AM
globenewswire.com logoProtalix BioTherapeutics to Hold Second Quarter 2017 Financial ... - GlobeNewswire (press release)
globenewswire.com - August 1 at 2:34 AM
finance.yahoo.com logoProtalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Corporate Update Conference Call on August 9, 2017
finance.yahoo.com - August 1 at 2:34 AM
globenewswire.com logoProtalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 ... - GlobeNewswire (press release)
globenewswire.com - July 27 at 6:27 AM
marketwatch.com logoConcurrently the Company Completes Private Placement of $10 Million Convertible Notes
www.marketwatch.com - July 26 at 6:26 AM
finance.yahoo.com logoProtalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022
finance.yahoo.com - July 26 at 6:26 AM
seekingalpha.com logoProCellEx Has The Potential To Upend The Biopharmaceutical Sector - Seeking Alpha
seekingalpha.com - July 2 at 6:30 AM
seekingalpha.com logoProtalix BioTherapeutics (PLX) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 8 at 8:08 PM
finance.yahoo.com logoProtalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility
finance.yahoo.com - June 1 at 8:06 PM
nasdaq.com logoAre Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock? - Nasdaq
www.nasdaq.com - May 31 at 1:07 PM
americanbankingnews.com logoRodman & Renshaw Reaffirms "Buy" Rating for Protalix Biotherapeutics Inc (PLX)
www.americanbankingnews.com - May 27 at 11:16 PM
globenewswire.com logoProtalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - May 27 at 2:30 AM
streetinsider.com logoProtalix BioTherapeutics (PLX) Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in CF - StreetInsider.com
www.streetinsider.com - May 25 at 12:35 AM
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 17 at 7:52 AM
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) CEO Moshe Manor Acquires 50,000 Shares
www.americanbankingnews.com - May 16 at 1:20 PM
finance.yahoo.com logoProtalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
finance.yahoo.com - May 12 at 8:02 PM
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) Issues Earnings Results
www.americanbankingnews.com - May 11 at 2:46 PM
finance.yahoo.com logoEdited Transcript of PLX earnings conference call or presentation 10-May-17 12:30pm GMT
finance.yahoo.com - May 11 at 8:40 AM
americanbankingnews.com logoProtalix Biotherapeutics (PLX) Earning Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 9 at 12:51 AM
americanbankingnews.com logoProtalix Biotherapeutics (PLX) Receives Daily Media Sentiment Score of 0.34
www.americanbankingnews.com - May 5 at 10:14 PM
seekingalpha.com logoProtalix BioTherapeutics Is Positioned Well For The Future
seekingalpha.com - April 21 at 12:23 AM
streetinsider.com logoProtalix BioTherapeutics (PLX) Announces New Data Demonstrating Positive Effect of PRX-102 - StreetInsider.com
www.streetinsider.com - April 19 at 9:51 AM
finance.yahoo.com logoProtalix BioTherapeutics Announces New Preclinical Results ... - Yahoo Finance
finance.yahoo.com - April 18 at 6:35 PM
americanbankingnews.com logoProtalix Biotherapeutics (PLX) Earns Coverage Optimism Score of 0.57
www.americanbankingnews.com - April 17 at 10:31 AM
americanbankingnews.com logoRodman & Renshaw Increases Protalix Biotherapeutics Inc (PLX) Price Target to $5.00
www.americanbankingnews.com - April 17 at 9:18 AM
seekingalpha.com logoProtalix BioTherapeutics: The DNase Treatment For Cystic Fibrosis And Opportunity For Profits - Seeking Alpha
seekingalpha.com - April 14 at 6:57 AM
rttnews.com logoAERI's Rocket Hits Target, ENTL Gets FDA Nod, NOVN Jumps On Positive Trial Data
www.rttnews.com - April 13 at 9:30 AM
streetinsider.com logoProtalix BioTherapeutics (PLX) Phase II Trial of alidornase alfa Shows Positive Results in CF
www.streetinsider.com - April 13 at 9:30 AM
finance.yahoo.com logoApricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials
finance.yahoo.com - April 13 at 9:30 AM
streetinsider.com logoProtalix BioTherapeutics (PLX) Phase II Trial of alidornase alfa Shows Positive Results in CF - StreetInsider.com
www.streetinsider.com - April 12 at 11:56 PM
finance.yahoo.com logoProtalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of alidornase alfa (AIR DNase™) for the Treatment of Cystic Fibrosis
finance.yahoo.com - April 12 at 1:50 PM
finance.yahoo.com logoDo Options Traders Know Something About Protalix (PLX) Stock We Don't?
finance.yahoo.com - April 7 at 11:56 AM
seekingalpha.com logoProtalix BioTherapeutics Looks Solid With Strong Pipeline - Protalix ... - Seeking Alpha
seekingalpha.com - March 27 at 6:43 PM
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 22 at 6:01 PM
seekingalpha.com logoProtalix BioTherapeutics: Exploring Ulcerative Colitis - Seeking Alpha
seekingalpha.com - March 16 at 8:31 AM
biz.yahoo.com logoQ4 2016 Protalix Biotherapeutics Inc Earnings Release - Time Not Supplied
biz.yahoo.com - March 16 at 8:31 AM
finance.yahoo.com logoProtalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update
finance.yahoo.com - March 16 at 8:31 AM
biz.yahoo.com logoPROTALIX BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition
biz.yahoo.com - March 16 at 8:31 AM
americanbankingnews.com logoProtalix Biotherapeutics Inc (PLX) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 15 at 8:19 AM
globenewswire.com logoProtalix BioTherapeutics to Hold Full-Year 2016 Financial Results and Corporate Update Conference Call on March 16 ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 7:06 PM
bizjournals.com logoTechnical Reports on Biotech Stocks -- Juno Therapeutics, Protalix BioTherapeutics, ImmunoGen, and ContraVir Pharma
www.bizjournals.com - February 23 at 8:58 AM
seekingalpha.com logoProtalix BioTherapeutics: New Institutional Ownership Swells Ahead Of Major Catalysts
seekingalpha.com - February 21 at 5:35 PM

Social

This page was last updated on 9/20/2017 by MarketBeat.com Staff